A Phase 1 interventional study of OPC-34712 (4mg) and Moxifloxacin in Schizophrenia and Schizoaffective Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2015-10-29.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 13th largest by enrollment, is one of 7 that started in 2011, is one of 8 in phase 1, and was the 8th registered.
3,567 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 218 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 48th largest by enrollment of the 111 interventional ones that give a count, is one of 9 that started in 2011, is one of 34 in phase 1, and was the 41st registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish pharmacodynamics (PD), pharmacokinetics (PK), and adverse event (AE) profile of OPC-34712 administered to schizophrenic/schizoaffective subjects. The goals of this trial are three-fold:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1 will be administered 4 mg OPC-34712 once daily (QD) for 11 days and OPC-34712 placebo for 1 day.
Drug: OPC-34712 (4mg) · Drug: Placebo
Arm 2 will be administered 12 mg OPC-34712 QD for 11 days and OPC-34712 placebo for 1 day.
Drug: OPC-34712 (12mg) · Drug: Placebo
Arm 3 will be administered 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for 1 day and OPC-34712 placebo QD for 11 days.
Drug: Moxifloxacin · Drug: Placebo
Arm 4 will be administered OPC-34712 placebo QD for 11 days and 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for one day.
Drug: Moxifloxacin · Drug: Placebo
Arms assigned to this intervention receive 4mg.
Arms assigned to this intervention will receive 400mg.
Arms assigned to this intervention receive 12mg.
OPC-34712 placebo
Time-matched QTcI Change From Baseline (Day -1) Corrected for Placebo on Day 11 Following Brexpiprazole Treatment.
Pharmacodynamics endpoint is the time-matched corrected QT interval (QTcI) change from baseline (Day -1) corrected for placebo on Day 11 following brexpiprazole treatment. The primary QT to QTc correction formula (QTcI) was determined for each participant using the participant's baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k was derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).
Time frame: Day 11 (Hours 1, 2, 3, 4, 5, 6, 8, 12, 16, 24)
Number of Participants With Adverse Events (AE) and Clinically Important Changes in Vital Signs, Physical Examinations, Laboratory Tests, and Standard ECGs (Electrocardiogram).
Clinically important changes in vital signs, physical examinations, laboratory tests and ECGs were by and large reflected in AE/SAE (which are presented in safety section) of this report.
Time frame: AEs were recorded from Screening (informed consent was signed) during the 12-day treatment period to follow-up 30 (+ 2) days post-last dose of study medication
Maximum Peak Plasma Concentration (Cmax) of Brexpiprazole and Moxifloxacin.
Pharmacokinetics endpoint is the maximum (peak) plasma concentration (Cmax) of brexpiprazole and moxifloxacin. Values for Cmax were determined directly from the observed data. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.
Time frame: Day 11
Time to Maximum (Peak) Plasma Concentration (Tmax) of Brexpiprazole and Moxifloxacin.
Pharmacokinetics endpoint is the time to maximum (peak) plasma concentration (tmax) of brexpiprazole and moxifloxacin. Values for tmax were determined directly from the observed data. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.
Time frame: Day 11
Area Under the Plasma Concentration-time Curve During Dosing (AUCT).
Pharmacokinetics endpoint is the area under the concentration-time curve from time zero to 24 hours (AUC0-24h) of brexpiprazole and moxifloxacin. Area under the plasma concentration-time curve during the dosing interval at steady-state (AUCT) value was estimated using the linear trapezoidal rule; the value reported represent the area under the curves to the last time point during that day. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.
Time frame: Day 11
Number of Participants Noted With Time-matched Change in Mean QTcI Change From Baseline for Assay Sensitivity of Moxifloxacin Treatment Corrected for Placebo at Day 11.
New onset (\> 450, \> 480, or \> 500 msec) in QTc was defined as a participant who attained a QTc \> 450, \> 480, \> 500 msec during Day 11 but not on Day -1. The number of participants were noted with time-matched change in mean QTcI change from Baseline for assay sensitivity of moxifloxacin treatment corrected for placebo. The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).
Time frame: Baseline, Day 11
Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Mean QTcI on Day -1 (Baseline).
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). The change form Baseline in summary of maximun QTcI on Day 11 minus mean QTcI on Day -1 (Baseline) is presented here.
Time frame: Baseline, Day 11
Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Maximum QTcI on Day -1 (Baseline).
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). The change from Baseline in summary of maximum QTcI on Day 11 minus maximum QTcI on Day -1 (Baseline) is presented here.
Time frame: Baseline, Day 11
Number of Participants With QTcI Interval Between 30 and 60 Msec on Day 11.
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). Participants with QTcI interval change between 30 to 60 msec were presented here.
Time frame: Day 11
Number of Participants With QTcI Interval > 60 Msec on Day 11.
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). Participants with QTcI interval change of \> 60 msec on Day 11 were presented here.
Time frame: Day 11
Number Participants Noted With New Incidence of QT Interval of > 500 Msec on Day 11.
The number of participants who were noted with new incidence of QT interval of \> 500 msec on Day 11 and a 12-lead ECG was used.
Time frame: Day 11
Number of Participants With New Incidence of ECG Morphology Abnormalities on Day 11.
Participants with incidence of ECG morphology abnormalities on Day 11 (participants who had abnormalities during Day 11 but not at Day -1) were noted. Types of abnormalities included appearance of abnormal U waves, negative T waves, elevation of ST segment, depression of ST segment, second degree heart block, third degree heart block, right bundle branch block, and left bundle branch block. ECGs were sampled at predose and approximately 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose on Days -1, 1, 11, and 12.
Time frame: Day 11
Number of Participants With Maximum Change From Baseline to the On-treatment ECG Values on Day 11 for Heart Rate (HR), PR Interval, and QRS Interval.
Changes in HR with values 25% decrease from Day -1 and HR \< 50 bpm and 25% increase from Day -1 and HR \> 100 bpm; PR interval of greater than or equal to 25% change from Day -1 and PR \> 200 msec; QRS interval of Greater than or equal to 25% change from Day -1 and \> 100 msec were noted on Day 11. Maximum change from baseline to the on-treatment ECG values on Day 11 for heart rate.
Time frame: Day 11
A randomized, double-blind, placebo and positive-controlled, parallel-arm study to examine the effects of 2 dose levels of brexpiprazole on the QT/QTc (QT interval corrected for heart rate) interval. This study was run in 8 sites in the US.
| Milestone | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin/Placebo |
|---|---|---|---|
| Started | 74 | 73 | 71 |
| Completed | 63 | 53 | 64 |
| Not completed | 11 | 20 | 7 |
| Withdrew: Adverse event | 5 | 9 | 2 |
| Withdrew: Met withdrawal criteria | 1 | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 10 | 3 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
Pharmacodynamics endpoint is the time-matched corrected QT interval (QTcI) change from baseline (Day -1) corrected for placebo on Day 11 following brexpiprazole treatment. The primary QT to QTc correction formula (QTcI) was determined for each participant using the participant's baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k was derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).
| msec | Moxifloxacin/Placebo | Brexpiprazole 12mg | Brexpiprazole 4mg |
|---|---|---|---|
| Hours 1 (N=61, 53, 61) | 9.2 (5.8 to 12.6) | -0.2 (-5.2 to 4.8) | 2.6 (-2.2 to 7.4) |
| Hours 2 (N= 62, 53, 62) | 9.4 (6.0 to 12.8) | -0.2 (-5.0 to 4.5) | 1.2 (-3.4 to 5.7) |
| Hours 3 (N= 60, 51, 61) | 8.5 (5.1 to 11.9) | 1.3 (-3.4 to 6.0) | 1.1 (-3.4 to 5.6) |
| Hours 4 (N= 62, 53, 62) | 10.5 (7.1 to 13.8) | 3.1 (-1.7 to 8.0) | 3.6 (-1.0 to 8.3) |
| Hours 5 (N= 62, 52, 62) | 6.2 (2.8 to 9.5) | -0.2 (-5.1 to 4.6) | 1.7 (-2.9 to 6.3) |
| Hours 6 (N= 61, 52, 62) | 7.3 (3.8 to 10.7) | 1.3 (-3.5 to 6.1) | 8.3 (-3.7 to 12.9) |
| Hours 8 (N= 59, 50, 59) | 7.5 (4.1 to 10.9) | 2.5 (-2.0 to 6.9) | 4.0 (-0.2 to 8.3) |
| Hours 10 (N= 59, 47, 56) | 9.0 (5.5 to 12.4) | 2.2 (-2.3 to 6.8) | 5.2 (0.8 to 9.5) |
| Hours 12 (N= 58, 47, 58) | 6.8 (3.3 to 10.3) | 2.6 (-2.2 to 7.4) | 5.3 (0.7 to 9.9) |
| Hours 16 (N= 59, 48, 53) | 2.2 (-1.3 to 5.7) | 0.8 (-3.9 to 5.5) | 4.0 (-0.6 to 8.5) |
| Hours 24 (N= 54, 45, 57) | 2.1 (-1.5 to 5.7) | 0.7 (-4.2 to 5.7) | 0.1 (-4.6 to 4.8) |
Clinically important changes in vital signs, physical examinations, laboratory tests and ECGs were by and large reflected in AE/SAE (which are presented in safety section) of this report.
| participants | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin | Placebo |
|---|---|---|---|---|
| Postural orthostatic tachycardia syndrome | 0 | 1 | 0 | 0 |
| Tachycardia | 0 | 0 | 2 | 1 |
| Blood creatinine phosphokinase increased | 1 | 1 | 0 | 0 |
| Blood pressure increased | 0 | 0 | 0 | 1 |
| Blood prolactin increased | 0 | 0 | 1 | 0 |
| Hepatic enzyme increased | 1 | 1 | 0 | 0 |
| Liver function test abnormal | 0 | 1 | 0 | 0 |
| Weight increased | 0 | 1 | 0 | 0 |
| Hyperglycaemia | 0 | 1 | 0 | 0 |
Pharmacokinetics endpoint is the maximum (peak) plasma concentration (Cmax) of brexpiprazole and moxifloxacin. Values for Cmax were determined directly from the observed data. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.
| ng/mL | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin/ Placebo |
|---|---|---|---|
| Maximum Peak Plasma Concentration (Cmax) of Brexpiprazole and Moxifloxacin. | 170 ± 69.8 | 462 ± 249 | 2760 ± 659 |
Pharmacokinetics endpoint is the time to maximum (peak) plasma concentration (tmax) of brexpiprazole and moxifloxacin. Values for tmax were determined directly from the observed data. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.
| Hours | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin/ Placebo |
|---|---|---|---|
| Time to Maximum (Peak) Plasma Concentration (Tmax) of Brexpiprazole and Moxifloxacin. | 3.54 (1.00 to 8.00) | 3.00 (0.00 to 8.00) | 1.25 (0.00 to 5.00) |
Pharmacokinetics endpoint is the area under the concentration-time curve from time zero to 24 hours (AUC0-24h) of brexpiprazole and moxifloxacin. Area under the plasma concentration-time curve during the dosing interval at steady-state (AUCT) value was estimated using the linear trapezoidal rule; the value reported represent the area under the curves to the last time point during that day. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.
| ng*h/mL | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin/ Placebo |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve During Dosing (AUCT). | 3100 ± 1400 | 8880 ± 5110 | 28400 ± 6350 |
New onset (\> 450, \> 480, or \> 500 msec) in QTc was defined as a participant who attained a QTc \> 450, \> 480, \> 500 msec during Day 11 but not on Day -1. The number of participants were noted with time-matched change in mean QTcI change from Baseline for assay sensitivity of moxifloxacin treatment corrected for placebo. The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).
| participants | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin 400 mg | Placebo |
|---|---|---|---|---|
| QTcI (> 450 msec) | 5 | 4 | 5 | 0 |
| QTcI (> 480 msec) | 0 | 1 | 0 | 0 |
| QTcI (> 500 msec) | 0 | 0 | 0 | 0 |
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). The change form Baseline in summary of maximun QTcI on Day 11 minus mean QTcI on Day -1 (Baseline) is presented here.
| msec | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Mean QTcI on Day -1 (Baseline). | 11.6 ± 7.4 | 12.4 ± 10.4 | 10.6 ± 7.7 | -1.1 ± 13.1 |
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). The change from Baseline in summary of maximum QTcI on Day 11 minus maximum QTcI on Day -1 (Baseline) is presented here.
| msec | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloaxcin 400mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Maximum QTcI on Day -1 (Baseline). | 0.4 ± 9.1 | 0.9 ± 10.9 | 0.0 ± 8.1 | -1.2 ± 8.0 |
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). Participants with QTcI interval change between 30 to 60 msec were presented here.
| participants | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Number of Participants With QTcI Interval Between 30 and 60 Msec on Day 11. | 4 | 1 | 11 | 2 |
The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). Participants with QTcI interval change of \> 60 msec on Day 11 were presented here.
| participants | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Number of Participants With QTcI Interval > 60 Msec on Day 11. | 0 | 0 | 0 | 0 |
The number of participants who were noted with new incidence of QT interval of \> 500 msec on Day 11 and a 12-lead ECG was used.
| participants | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| Number Participants Noted With New Incidence of QT Interval of > 500 Msec on Day 11. | 0 | 0 | 0 | 0 |
Participants with incidence of ECG morphology abnormalities on Day 11 (participants who had abnormalities during Day 11 but not at Day -1) were noted. Types of abnormalities included appearance of abnormal U waves, negative T waves, elevation of ST segment, depression of ST segment, second degree heart block, third degree heart block, right bundle branch block, and left bundle branch block. ECGs were sampled at predose and approximately 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose on Days -1, 1, 11, and 12.
| participants | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin 400mg | Placebo |
|---|---|---|---|---|
| U Wave abnormalities | 0 | 0 | 0 | 0 |
| Negative T Waves | 4 | 7 | 8 | 6 |
| Depression of ST segment | 2 | 2 | 4 | 1 |
| Elevation of ST segment | 0 | 0 | 0 | 0 |
| Second degree heart block | 0 | 0 | 0 | 0 |
| Third degree heart block | 0 | 0 | 0 | 0 |
| Right bundle branch block | 0 | 0 | 0 | 0 |
| Left bundle branch block | 0 | 0 | 0 | 0 |
Changes in HR with values 25% decrease from Day -1 and HR \< 50 bpm and 25% increase from Day -1 and HR \> 100 bpm; PR interval of greater than or equal to 25% change from Day -1 and PR \> 200 msec; QRS interval of Greater than or equal to 25% change from Day -1 and \> 100 msec were noted on Day 11. Maximum change from baseline to the on-treatment ECG values on Day 11 for heart rate.
| participants | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin | Placebo |
|---|---|---|---|---|
| HR: < 50 bpm | 0 | 0 | 0 | 0 |
| HR: > 100 bpm | 5 | 7 | 2 | 4 |
| PR > 200 msec | 0 | 0 | 0 | 0 |
| QRS > 100 msec | 0 | 0 | 0 | 0 |
Collected over AEs were recorded from Screening (informed consent was signed) throughout the 12-day treatment period until follow-up of up to 30 (+ 2) days post-last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole 4mg | — | 1/70 (1.4%) | 27/70 (38.6%) |
| Brexpiprazole 12mg | — | 0/67 (0%) | 27/67 (40.3%) |
| Moxifloxacin | — | 0/65 (0%) | 9/65 (13.8%) |
| Placebo | — | 0/68 (0%) | 20/68 (29.4%) |
| Event | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin | Placebo |
|---|---|---|---|---|
| Schizoaffective disorderPsychiatric disorders | 1/70 | 0/67 | 0/65 | 0/68 |
| Event | Brexpiprazole 4mg | Brexpiprazole 12mg | Moxifloxacin | Placebo |
|---|---|---|---|---|
| DizzinessNervous system disorders | 6/70 | 8/67 | 2/65 | 1/68 |
| NauseaGastrointestinal disorders | 7/70 | 5/67 | 1/65 | 4/68 |
| Application site dermatitisGeneral disorders | 6/70 | 1/67 | 2/65 | 4/68 |
| AkathisiaNervous system disorders | 5/70 | 5/67 | 1/65 | 1/68 |
| Extrapyramidal disorderNervous system disorders | 4/70 | 5/67 | 0/65 | 1/68 |
| RestlessnessPsychiatric disorders | 2/70 | 5/67 | 0/65 | 3/68 |
| HeadacheNervous system disorders | 1/70 | 5/67 | 2/65 | 4/68 |
| ConstipationGastrointestinal disorders | 3/70 | 4/67 | 1/65 | 1/68 |
| SomnolenceNervous system disorders | 3/70 | 4/67 | 1/65 | 1/68 |
| InsomniaPsychiatric disorders | 3/70 | 4/67 | 0/65 | 3/68 |
| Age, Continuous(Years) | Brexpiprazole 4mg | Brexpiprzole 12mg | Moxifloxacin/Placebo | Total |
|---|---|---|---|---|
| Mean | 38.5 ± 9.6 | 37.5 ± 9.0 | 38.2 ± 9.6 | 38.1 ± 9.4 |
| Sex: Female, Male(Participants) | Brexpiprazole 4mg | Brexpiprzole 12mg | Moxifloxacin/Placebo | Total |
|---|---|---|---|---|
| Female | 18 | 16 | 15 | 49 |
| Male | 56 | 57 | 56 | 169 |
The record gives a start of Jul 2011, a primary completion of Feb 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brexpiprazole · Moxifloxacin
Otsuka Pharmaceutical Development & Commercialization, Inc. →